» Articles » PMID: 33562306

Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Feb 10
PMID 33562306
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer (OC) is the deadliest gynecologic cancer, due to late diagnosis, development of platinum resistance, and inadequate alternative therapy. It has been demonstrated that membrane ion channels play important roles in cancer processes, including cell proliferation, apoptosis, motility, and invasion. Here, we review the contribution of ion channels in the development and progression of OC, evaluating their potential in clinical management. Increased expression of voltage-gated and epithelial sodium channels has been detected in OC cells and tissues and shown to be involved in cancer proliferation and invasion. Potassium and calcium channels have been found to play a critical role in the control of cell cycle and in the resistance to apoptosis, promoting tumor growth and recurrence. Overexpression of chloride and transient receptor potential channels was found both in vitro and in vivo, supporting their contribution to OC. Furthermore, ion channels have been shown to influence the sensitivity of OC cells to neoplastic drugs, suggesting a critical role in chemotherapy resistance. The study of ion channels expression and function in OC can improve our understanding of pathophysiology and pave the way for identifying ion channels as potential targets for tumor diagnosis and treatment.

Citing Articles

Extracellular Regucalcin: A Potent Suppressor in the Cancer Cell Microenvironment.

Yamaguchi M Cancers (Basel). 2025; 17(2).

PMID: 39858022 PMC: 11763602. DOI: 10.3390/cancers17020240.


Molecular landscape of borderline ovarian tumours: A systematic review.

Sadlecki P, Walentowicz-Sadlecka M Open Med (Wars). 2024; 19(1):20240976.

PMID: 38859878 PMC: 11163159. DOI: 10.1515/med-2024-0976.


Regucalcin Is a Potential Regulator in Human Cancer: Aiming to Expand into Cancer Therapy.

Yamaguchi M Cancers (Basel). 2023; 15(22).

PMID: 38001749 PMC: 10670417. DOI: 10.3390/cancers15225489.


Calcium signals and potential therapy targets in ovarian cancer (Review).

Deng F, Fu M, Zhao C, Lei J, Xu T, Ji B Int J Oncol. 2023; 63(5).

PMID: 37711071 PMC: 10552713. DOI: 10.3892/ijo.2023.5573.


Voltage-gated sodium channels: from roles and mechanisms in the metastatic cell behavior to clinical potential as therapeutic targets.

Sanchez-Sandoval A, Hernandez-Plata E, Gomora J Front Pharmacol. 2023; 14:1206136.

PMID: 37456756 PMC: 10348687. DOI: 10.3389/fphar.2023.1206136.


References
1.
Dziegielewska B, Casarez E, Yang W, Gray L, Dziegielewski J, Slack-Davis J . T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin. Mol Cancer Ther. 2016; 15(3):460-70. PMC: 4783280. DOI: 10.1158/1535-7163.MCT-15-0456. View

2.
Singha B, Harper S, Goldman A, Bitler B, Aird K, Borowsky M . CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep. 2018; 8(1):14725. PMC: 6170428. DOI: 10.1038/s41598-018-32885-2. View

3.
Jaber N, Dou Z, Lin R, Zhang J, Zong W . Mammalian PIK3C3/VPS34: the key to autophagic processing in liver and heart. Autophagy. 2012; 8(4):707-8. PMC: 3679090. DOI: 10.4161/auto.19627. View

4.
Zhi D, Zhou K, Yu D, Fan X, Zhang J, Li X . hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells. Oncol Lett. 2019; 17(6):5653-5661. PMC: 6507338. DOI: 10.3892/ol.2019.10263. View

5.
Zeng B, Yuan C, Yang X, Atkin S, Xu S . TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr Cancer Drug Targets. 2012; 13(1):103-16. View